Article

Melanoma Survivors Encourage Others to Protect Their Skin

Melanoma is the second most common form of cancer for young people ages 15-29. It is a disease that affects a younger population. But the good news is it’s preventable. By taking proper precautions and checking yourself monthly, you can protect yourself against melanoma.

Hear young survivors share their stories of survival.

https://vimeo.com/161458528

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
Is There a New Standard Way to Treat Advanced-Stage Melanoma?
Image of patient and doctor.
Understanding the Whole Person Behind their Cancer Diagnosis
Image of Dr. Doug
Expert Shares Key Insights During Melanoma Awareness Month
Immune Therapy Expands Melanoma Treatment to More Patients
Immune Therapy Expands Melanoma Treatment to More Patients
Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors
Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors
Image of a man with dark hair and some facial hair.
Addressing Pros and Cons of CAR-T Cell Therapy in Melanoma
Image of a man with blond facial hair.
TIL Therapy Uses the Body’s Own Cells to Attack Cancer Cells in Melanoma
Image of a woman with blond hai
Patients With Stage 3 Melanoma Should Discuss Adjuvant Therapy
Dr. Manisha Thakuria in an interview with CURE
Cases of Merkel Cell Carcinoma, ‘a Cancer of Older Adults’ are Rising
Dr. Beth Goldstein in an interview with CURE
Tanning Beds Are the ‘Worst Offenders’ for Skin Cancer, Dermatologist Says
Related Content
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects: © stock.adobe.com.
July 24th 2025

New Treatment Combo Improves Advanced Melanoma Outcomes

Spencer Feldman
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of man with text..
July 17th 2025

Key Skin Cancer Treatment Updates From 2025 and What is Still to Come

Ryan Scott
Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for patients with high-risk skin cancer.
Top Cancer Headlines from 2023
January 2nd 2024

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
A A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma: © stock.adobe.com.
July 14th 2025

Real-World Data Supports Amtagvi’s Benefit in Advanced Melanoma

Spencer Feldman
A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.
TIL therapy is on the rise in melanoma, with potential for other tumor types.
July 6th 2025

Empowering the Immune System

Darlene Dobkowski, MA
TIL therapy is on the rise in melanoma, with potential for other tumor types.